TY - JOUR
T1 - Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome
AU - Ehrmann, David A.
AU - Liljenquist, David R.
AU - Kasza, Kristen
AU - Azziz, Ricardo
AU - Legro, Richard S.
AU - Ghazzi, Mahmoud N.
AU - Aronoff, Stephen
AU - Bernstein, Richard
AU - Bodenner, Donald
AU - Braithwaite, Susan
AU - Cohen, Joshua
AU - DePaolo, David
AU - Einhorn, Daniel
AU - Hone, Jennifer
AU - Kenshole, Anne
AU - Kilo, Charles
AU - Kjos, Siri Linda
AU - Korytkowski, Mary
AU - Koster, Diane
AU - Lau, Rebecca
AU - Lobo, Rogerio
AU - Lucas, Jean
AU - Martin, Kathryn
AU - Meyer, William
AU - Pek, Sumer
AU - Pfeifer, Samantha
AU - Rebar, Robert
AU - Redmond, Geoffrey
AU - Rittmaster, Roger
AU - Ross, Peter
AU - Schwartz, Sherwyn
AU - Wild, Robert
AU - Yen, Samuel S.C.
PY - 2006/1
Y1 - 2006/1
N2 - Context: Polycystic ovary syndrome (PCOS) and the metabolic syndrome have many features in common and may share the same pathogenesis. Objective: This study was performed to determine the prevalence and predictors of the metabolic syndrome in PCOS. Design: The clinical, hormonal, and oral glucose tolerance test results were analyzed in 394 PCOS women who were screened for participation in a multicenter trial to evaluate the effects of troglitazone on ovulation and hirsutism. Setting: A multicenter clinical trial is presented. Patients or Other Participants: The subjects were women with PCOS who had or lacked the metabolic syndrome. Main Outcome Measures: Waist circumference, fasting glucose, high-density lipoprotein cholesterol and triglyceride concentrations, and blood pressure were the main outcome measures. Results: Twenty-six (6.6%) subjects had diabetes; among the 368 nondiabetics, the prevalence for individual components comprising the metabolic syndrome were: waist circumference greater than 88 cm in 80%, high-density lipoprotein cholesterol less than 50 mg/dl in 66%, triglycerides greater than or equal to 150 mg/dl in 32%, blood pressure greater than or equal to 130/85 mm Hg in 21%, and fasting glucose concentrations greater than or equal to 110 mg/dl in 5%. Three or more of these individual criteria were present in 123 (33.4%) subjects overall. The prevalence of the metabolic syndrome did not differ significantly between racial/ethnic groups. The prevalence of the metabolic syndrome from lowest to highest quartile of free testosterone concentration was 19.8, 31.3, 46.9, and 35.0%, respectively [P = 0.056 adjusted for body mass index (BMI)]. None of the 52 women with a BMI less than 27.0 kg/m2 had the metabolic syndrome; those in the top BMI quartile were 13.7 times more likely (95% confidence interval, 5.7-33.0) to have the metabolic syndrome compared with those in the lowest quartile. Thirty-eight percent of those with the metabolic syndrome had impaired glucose tolerance compared with 19% without the metabolic syndrome (P < 0.001). Conclusions: The metabolic syndrome and its individual components are common in PCOS, particularly among women with the highest insulin levels and BMI. Hyperinsulinemia is a likely common pathogenetic factor for both PCOS and the metabolic syndrome.
AB - Context: Polycystic ovary syndrome (PCOS) and the metabolic syndrome have many features in common and may share the same pathogenesis. Objective: This study was performed to determine the prevalence and predictors of the metabolic syndrome in PCOS. Design: The clinical, hormonal, and oral glucose tolerance test results were analyzed in 394 PCOS women who were screened for participation in a multicenter trial to evaluate the effects of troglitazone on ovulation and hirsutism. Setting: A multicenter clinical trial is presented. Patients or Other Participants: The subjects were women with PCOS who had or lacked the metabolic syndrome. Main Outcome Measures: Waist circumference, fasting glucose, high-density lipoprotein cholesterol and triglyceride concentrations, and blood pressure were the main outcome measures. Results: Twenty-six (6.6%) subjects had diabetes; among the 368 nondiabetics, the prevalence for individual components comprising the metabolic syndrome were: waist circumference greater than 88 cm in 80%, high-density lipoprotein cholesterol less than 50 mg/dl in 66%, triglycerides greater than or equal to 150 mg/dl in 32%, blood pressure greater than or equal to 130/85 mm Hg in 21%, and fasting glucose concentrations greater than or equal to 110 mg/dl in 5%. Three or more of these individual criteria were present in 123 (33.4%) subjects overall. The prevalence of the metabolic syndrome did not differ significantly between racial/ethnic groups. The prevalence of the metabolic syndrome from lowest to highest quartile of free testosterone concentration was 19.8, 31.3, 46.9, and 35.0%, respectively [P = 0.056 adjusted for body mass index (BMI)]. None of the 52 women with a BMI less than 27.0 kg/m2 had the metabolic syndrome; those in the top BMI quartile were 13.7 times more likely (95% confidence interval, 5.7-33.0) to have the metabolic syndrome compared with those in the lowest quartile. Thirty-eight percent of those with the metabolic syndrome had impaired glucose tolerance compared with 19% without the metabolic syndrome (P < 0.001). Conclusions: The metabolic syndrome and its individual components are common in PCOS, particularly among women with the highest insulin levels and BMI. Hyperinsulinemia is a likely common pathogenetic factor for both PCOS and the metabolic syndrome.
UR - https://www.scopus.com/pages/publications/30344448576
UR - https://www.scopus.com/pages/publications/30344448576#tab=citedBy
U2 - 10.1210/jc.2005-1329
DO - 10.1210/jc.2005-1329
M3 - Article
C2 - 16249284
AN - SCOPUS:30344448576
SN - 0021-972X
VL - 91
SP - 48
EP - 53
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 1
ER -
